ProQR IPO is this week. Their leading product is QR-010 which aims to restore the defect in CFTR protein caused by the del F508 mutation. Specifically, administration into the lungs of a chemically modified oligoribonucleotide that is capable of restoring the RNA sequence coding for CFTR, thereby restoring CFTR protein function, or at least improving it. Administration would be via a nebulized drug+hypertonic saline solution. Cost is not yet known to me. IPO is for the rollout of phase 1 clinical trials.
For those interesting in reading up on the specifics below are the resources. Please feel free to share your findings and thoughts! I will be studying these over time and the first clinical trial role out.
Comment like and share on our Facebook: https://www.facebook.com/knowcf/posts/10152818107593777
- Chris
For those interesting in reading up on the specifics below are the resources. Please feel free to share your findings and thoughts! I will be studying these over time and the first clinical trial role out.
Comment like and share on our Facebook: https://www.facebook.com/knowcf/posts/10152818107593777
- Chris